<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01970696</url>
  </required_header>
  <id_info>
    <org_study_id>International OTST Registry</org_study_id>
    <nct_id>NCT01970696</nct_id>
  </id_info>
  <brief_title>International Ovarian &amp; Testicular Stromal Tumor Registry</brief_title>
  <acronym>OTST</acronym>
  <official_title>International Ovarian &amp; Testicular Stromal Tumor Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospitals and Clinics of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Colorado</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rutgers University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Klinikum Dortmund Wirbelsäulenchirurgie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ResourcePath</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospitals and Clinics of Minnesota</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rare tumors are understudied, yet have the potential to shed light on vast areas of cancer
      research. Ovarian sex cord-stromal tumors, rare tumors of childhood and young adulthood, have
      recently been found to be associated with a lung cancer of early childhood called
      pleuropulmonary blastoma (PPB). The cause of these ovarian tumors is unknown. DICER1
      mutations are seen in the majority of children with PPB. Research shows DICER1 mutations are
      also seen in some patients with ovarian tumors. Like PPB, ovarian stromal tumors are highly
      curable when found in early stage; however, later forms of the disease are aggressive and
      often fatal. The International Ovarian Stromal Tumor Registry collects clinical and biologic
      data to understand why these tumors occur and how to treat them. Current work involves the
      study of the role of DICER1 and miRNA expression in ovarian stromal tumors. Understanding the
      clinical history, predisposing factors and DICER1 and miRNA expression in these ovarian
      tumors of childhood will lead to targeted screening and risk stratification for
      evidence-based treatment and biologically rational therapies. These efforts will improve the
      lives of children by increasing survival and reducing late effects.

      The specific goals of the International Ovarian and Testicular Stromal Tumor Registry are:

        1. to understand risk factors by studying age, pathologic subtype, histopathologic
           features, tumor invasiveness, degree of differentiation, presence of metastasis

        2. to collect information on personal and family history in order to refine the clinical
           characteristics of patients and families with and without germline DICER1 mutations and
           other genetic predisposing factors

        3. to determine whether there is a pattern of gene expression or DNA alterations that
           correlate with predisposition to ovarian tumors, biologic behavior and clinical outcome

        4. to determine optimal screening regimens

        5. to use clinical data obtained through the Registry to refine treatment algorithms

        6. to establish a collection of annotated biology specimens (tumor tissue and germline DNA)
           for future research
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Registry collects and analyzes case-by-case data on ovarian stromal tumors. Cases are
      identified:

        1. by referrals from clinicians or pathologists

        2. by families initiating contact with the Registry

        3. by Registry requests to authors of published cases to share further details

      The data collected include:

        1. clinical and laboratory findings

        2. family history

        3. imaging studies

        4. surgery records

        5. pathology records including review and study of pathology materials

        6. treatment (surgery, chemotherapy, radiation)

        7. recurrences or metastases

        8. long-term follow-up

      The demographic and clinical data are abstracted into a database secured by password
      protection. Each record in the database has a unique Registry number.

      Enrollment in the OTST Registry is based on local diagnosis, but central pathology review is
      offered as a part of Registry procedures.

      For each patient enrolled, the Registry will request 1) whole blood for DNA extraction and
      lymphoblastoid cell line generation 2) slides or snap frozen tumor tissue (if available), and
      3) paraffin blocks. In some cases, saliva samples, buccal swabs or urine samples will be
      obtained for DNA extraction.

      Pathology materials are centrally reviewed when available. Any discrepancies in the
      diagnostic interpretation are discussed with the submitting pathologist or clinician. When
      the central review pathologist cannot confirm diagnosis of a stromal tumor, the referring
      physician is notified. The local pathologist retains responsibility for the final
      pathological diagnosis. It is the responsibility of the referring physician to notify the
      patient regarding any discrepancy found.

      Biologic specimens will be banked and stored for future research.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2011</start_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>DICER1 mutations in ovarian and testicular stromal tumors</measure>
    <time_frame>3 years</time_frame>
    <description>We will analyze germline DNA from patients with gonadal stromal tumors to determine the presence of DICER1 mutations. The tumor tissue will also be sequenced. mRNA and miRNA expression will be analyzed on tumor tissue. Results of the above will be correlated with clinical outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical factors associated with outcome in ovarian and testicular stromal tumors</measure>
    <time_frame>3 years</time_frame>
    <description>We will analyze the clinical records to determine which factors influence prognosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathologic and Genetic Correlations</measure>
    <time_frame>3 years</time_frame>
    <description>We will correlate the pathologic and genetic data with clinical data to describe factors associated with poor prognosis.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Ovarian Stromal Tumor</condition>
  <condition>Testicular Stromal Tumors</condition>
  <condition>Ovarian Small Cell Carcinoma</condition>
  <condition>DICER1 Syndrome</condition>
  <arm_group>
    <arm_group_label>Ovarian Stromal Tumors</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Testicular Stromal Tumors</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Ovarian Small Cell Carcinoma</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      1) whole blood for DNA extraction and lymphoblastoid cell line generation, 2) stained and
      unstained slides and snap frozen tumor tissue (if available), and 3) paraffin blocks.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Prospectively or retrospectively diagnosed patients with ovarian or testicular stromal
        tumors or ovarian small cell carcinoma
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previous or current diagnosis of an ovarian sex cord stromal including but not limited
             to: Sertoli-Leydig cell tumor, gynandroblastoma, juvenile granulosa cell tumor,
             Sertoli cell tumor, sex cord stromal tumor with annular tubules or undifferentiated
             stromal tumor

          -  Previous or current diagnosis of a testicular stromal tumor including but not limited
             to: juvenile granulosa cell tumor, Sertoli cell tumor, Leydig cell tumor or
             undifferentiated stromal tumor

        Exclusion Criteria:

          -  No clinical or biologic material available for review

          -  Unable to provide informed consent/assent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kris Ann P Schultz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Minnesota</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne Harris, MPH</last_name>
    <phone>612-813-5861</phone>
    <email>anne.harris@childrensmn.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kris Ann P Schultz, MD, MS</last_name>
      <phone>612-813-5940</phone>
      <email>OTST@childrensMN.org</email>
    </contact>
    <contact_backup>
      <last_name>Anne K Harris</last_name>
      <phone>612-813-5861</phone>
      <email>OTST@childrensMN.org</email>
    </contact_backup>
    <investigator>
      <last_name>Kris Ann P Schultz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.OTSTregistry.org</url>
    <description>International OTST Registry official website</description>
  </link>
  <link>
    <url>http://www.PPBregistry.org</url>
    <description>International PPB Registry</description>
  </link>
  <reference>
    <citation>Schultz KA, Schneider DT, Pashankar F, Ross J, Frazier L. Management of ovarian and testicular sex cord-stromal tumors in children and adolescents. J Pediatr Hematol Oncol. 2012 May;34 Suppl 2:S55-63. doi: 10.1097/MPH.0b013e31824e3867. Review.</citation>
    <PMID>22525408</PMID>
  </reference>
  <reference>
    <citation>Doros L, Yang J, Dehner L, Rossi CT, Skiver K, Jarzembowski JA, Messinger Y, Schultz KA, Williams G, André N, Hill DA. DICER1 mutations in embryonal rhabdomyosarcomas from children with and without familial PPB-tumor predisposition syndrome. Pediatr Blood Cancer. 2012 Sep;59(3):558-60. doi: 10.1002/pbc.24020. Epub 2011 Dec 16.</citation>
    <PMID>22180160</PMID>
  </reference>
  <reference>
    <citation>Schultz KA, Pacheco MC, Yang J, Williams GM, Messinger Y, Hill DA, Dehner LP, Priest JR. Ovarian sex cord-stromal tumors, pleuropulmonary blastoma and DICER1 mutations: a report from the International Pleuropulmonary Blastoma Registry. Gynecol Oncol. 2011 Aug;122(2):246-50. doi: 10.1016/j.ygyno.2011.03.024. Epub 2011 Apr 17.</citation>
    <PMID>21501861</PMID>
  </reference>
  <reference>
    <citation>Schultz KA, Sencer SF, Messinger Y, Neglia JP, Steiner ME. Pediatric ovarian tumors: a review of 67 cases. Pediatr Blood Cancer. 2005 Feb;44(2):167-73.</citation>
    <PMID>15490488</PMID>
  </reference>
  <reference>
    <citation>Schultz KA, Ness KK, Nagarajan R, Steiner ME. Adnexal masses in infancy and childhood. Clin Obstet Gynecol. 2006 Sep;49(3):464-79. Review.</citation>
    <PMID>16885654</PMID>
  </reference>
  <reference>
    <citation>Rio Frio T, Bahubeshi A, Kanellopoulou C, Hamel N, Niedziela M, Sabbaghian N, Pouchet C, Gilbert L, O'Brien PK, Serfas K, Broderick P, Houlston RS, Lesueur F, Bonora E, Muljo S, Schimke RN, Bouron-Dal Soglio D, Arseneau J, Schultz KA, Priest JR, Nguyen VH, Harach HR, Livingston DM, Foulkes WD, Tischkowitz M. DICER1 mutations in familial multinodular goiter with and without ovarian Sertoli-Leydig cell tumors. JAMA. 2011 Jan 5;305(1):68-77. doi: 10.1001/jama.2010.1910.</citation>
    <PMID>21205968</PMID>
  </reference>
  <reference>
    <citation>Doros L, Schultz KA, Stewart DR, Bauer AJ, Williams G, Rossi CT, Carr A, Yang J, Dehner LP, Messinger Y, Hill DA. DICER1-Related Disorders. 2014 Apr 24. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018. Available from http://www.ncbi.nlm.nih.gov/books/NBK196157/</citation>
    <PMID>24761742</PMID>
  </reference>
  <reference>
    <citation>Pappo AS, Furman WL, Schultz KA, Ferrari A, Helman L, Krailo MD. Rare Tumors in Children: Progress Through Collaboration. J Clin Oncol. 2015 Sep 20;33(27):3047-54. doi: 10.1200/JCO.2014.59.3632. Epub 2015 Aug 24. Review.</citation>
    <PMID>26304909</PMID>
  </reference>
  <reference>
    <citation>Messinger YH, Stewart DR, Priest JR, Williams GM, Harris AK, Schultz KA, Yang J, Doros L, Rosenberg PS, Hill DA, Dehner LP. Pleuropulmonary blastoma: a report on 350 central pathology-confirmed pleuropulmonary blastoma cases by the International Pleuropulmonary Blastoma Registry. Cancer. 2015 Jan 15;121(2):276-85. doi: 10.1002/cncr.29032. Epub 2014 Sep 10.</citation>
    <PMID>25209242</PMID>
  </reference>
  <reference>
    <citation>Schultz KA, Harris A, Williams GM, Baldinger S, Doros L, Valusek P, Frazier AL, Dehner LP, Messinger Y, Hill DA. Reply: Serum microRNA screening for DICER1-associated pleuropulmonary blastoma. Pediatr Blood Cancer. 2014 Dec;61(12):2331-2. doi: 10.1002/pbc.25233. Epub 2014 Sep 22.</citation>
    <PMID>25251372</PMID>
  </reference>
  <reference>
    <citation>Doros LA, Rossi CT, Yang J, Field A, Williams GM, Messinger Y, Cajaiba MM, Perlman EJ, A Schultz K, Cathro HP, Legallo RD, LaFortune KA, Chikwava KR, Faria P, Geller JI, Dome JS, Mullen EA, Gratias EJ, Dehner LP, Hill DA. DICER1 mutations in childhood cystic nephroma and its relationship to DICER1-renal sarcoma. Mod Pathol. 2014 Sep;27(9):1267-80. doi: 10.1038/modpathol.2013.242. Epub 2014 Jan 31.</citation>
    <PMID>24481001</PMID>
  </reference>
  <reference>
    <citation>Stewart DR, Messinger Y, Williams GM, Yang J, Field A, Schultz KA, Harney LA, Doros LA, Dehner LP, Hill DA. Nasal chondromesenchymal hamartomas arise secondary to germline and somatic mutations of DICER1 in the pleuropulmonary blastoma tumor predisposition disorder. Hum Genet. 2014 Nov;133(11):1443-50. doi: 10.1007/s00439-014-1474-9. Epub 2014 Aug 14.</citation>
    <PMID>25118636</PMID>
  </reference>
  <reference>
    <citation>Pashankar F, Bisogno G, Ribeiro R, Messinger Y, Schultz KA, Rodriguez-Galindo C. The role of registries and tumor banking in rare pediatric tumors. Curr Pediatr Rep 2015:1-9. Avail online 15 Mar 2015. DOI 10.1007/s40124-015-0077-9.</citation>
  </reference>
  <reference>
    <citation>Schultz KAP and Miller R. (2014) Adnexal Masses in Infancy and Childhood. Coomarasamy A, Davuka W, Shafi M, Chan C (eds): Gynecology and Obstetric Surgery: Challenges and Management Options. Wiley-Blackwell. [BOOK.] [In press; avail may 2015].</citation>
  </reference>
  <reference>
    <citation>Schultz KAP, Frazier L, Schneider DT. (2014) Ovarian and Testicular Sex Cord Stromal Tumors. Frazier, AL, Amatruda JF (eds): Textbook Pediatric Germ Cell Tumors, Pediatric Oncology 1. Berlin Heidelberg. Springer-Verlag. [BOOK.].</citation>
  </reference>
  <reference>
    <citation>Messinger YH, Schultz KAP, Dehner LP. (2012) Uncommon Pediatric Tumors of the Thorax. In Raghavan D , Blanke CD, Johnson DH, Moots PL, Reaman GH, Rose PG, Sekeres MA (Eds): Textbook of Uncommon Cancer, 4th Edition. Hoboken, (877-901) New Jersey. John Wiley &amp; Sons, Inc. [BOOK.].</citation>
  </reference>
  <reference>
    <citation>Khan NE, Bauer AJ, Doros L, Schultz KA, Decastro RM, Harney LA, Kase RG, Carr AG, Harris AK, Williams GM, Dehner LP, Messinger YH, Stewart DR. Macrocephaly associated with the DICER1 syndrome. Genet Med. 2017 Feb;19(2):244-248. doi: 10.1038/gim.2016.83. Epub 2016 Jul 21.</citation>
    <PMID>27441995</PMID>
  </reference>
  <reference>
    <citation>Stewart DR, Givens SS, Harris AK, Williams GM, Messinger YH, Schultz KA, Hill DA. Comment on: DICER1-Negative Pleuropulmonary Blastoma in a Patient With Selective IgA Deficiency. Pediatr Blood Cancer. 2016 Oct;63(10):1869-70. doi: 10.1002/pbc.26075. Epub 2016 May 30.</citation>
    <PMID>27238822</PMID>
  </reference>
  <reference>
    <citation>Dehner LP, Messinger YH, Schultz KA, Williams GM, Wikenheiser-Brokamp K, Hill DA. Pleuropulmonary Blastoma: Evolution of an Entity as an Entry into a Familial Tumor Predisposition Syndrome. Pediatr Dev Pathol. 2015 Nov-Dec;18(6):504-11. doi: 10.2350/15-10-1732-OA.1. Epub 2015 Dec 23.</citation>
    <PMID>26698637</PMID>
  </reference>
  <reference>
    <citation>Rove KO, Maroni PD, Cost CR, Fairclough DL, Giannarini G, Harris AK, Schultz KA, Cost NG. Pathologic Risk Factors in Pediatric and Adolescent Patients With Clinical Stage I Testicular Stromal Tumors. J Pediatr Hematol Oncol. 2015 Nov;37(8):e441-6. doi: 10.1097/MPH.0000000000000445. Review.</citation>
    <PMID>26479987</PMID>
  </reference>
  <reference>
    <citation>Feinberg A, Hall NJ, Williams GM, Schultz KA, Miniati D, Hill DA, Dehner LP, Messinger YH, Langer JC. Can congenital pulmonary airway malformation be distinguished from Type I pleuropulmonary blastoma based on clinical and radiological features? J Pediatr Surg. 2016 Jan;51(1):33-7. doi: 10.1016/j.jpedsurg.2015.10.019. Epub 2015 Oct 23.</citation>
    <PMID>26561249</PMID>
  </reference>
  <reference>
    <citation>Brenneman M, Field A, Yang J, Williams G, Doros L, Rossi C, Schultz KA, Rosenberg A, Ivanovich J, Turner J, Gordish-Dressman H, Stewart D, Yu W, Harris A, Schoettler P, Goodfellow P, Dehner L, Messinger Y, Hill DA. Temporal order of RNase IIIb and loss-of-function mutations during development determines phenotype in DICER1 syndrome: a unique variant of the two-hit tumor suppression model. F1000Res. 2015 Jul 10;4:214. doi: 10.12688/f1000research.6746.1. eCollection 2015.</citation>
    <PMID>26925222</PMID>
  </reference>
  <results_reference>
    <citation>Schultz KA, Harris A, Williams GM, Baldinger S, Doros L, Valusek P, Frazier AL, Dehner LP, Messinger Y, Hill DA. Judicious DICER1 testing and surveillance imaging facilitates early diagnosis and cure of pleuropulmonary blastoma. Pediatr Blood Cancer. 2014 Sep;61(9):1695-7. doi: 10.1002/pbc.25092. Epub 2014 May 13.</citation>
    <PMID>24821309</PMID>
  </results_reference>
  <results_reference>
    <citation>Schultz KA, Yang J, Doros L, Williams GM, Harris A, Stewart DR, Messinger Y, Field A, Dehner LP, Hill DA. DICER1-pleuropulmonary blastoma familial tumor predisposition syndrome: a unique constellation of neoplastic conditions. Pathol Case Rev. 2014 Mar;19(2):90-100.</citation>
    <PMID>25356068</PMID>
  </results_reference>
  <results_reference>
    <citation>Schultz KA, Harris A, Messinger Y, Sencer S, Baldinger S, Dehner LP, Hill DA. Ovarian tumors related to intronic mutations in DICER1: a report from the international ovarian and testicular stromal tumor registry. Fam Cancer. 2016 Jan;15(1):105-10. doi: 10.1007/s10689-015-9831-y.</citation>
    <PMID>26289771</PMID>
  </results_reference>
  <results_reference>
    <citation>Rutter MM, Jha P, Schultz KA, Sheil A, Harris AK, Bauer AJ, Field AL, Geller J, Hill DA. DICER1 Mutations and Differentiated Thyroid Carcinoma: Evidence of a Direct Association. J Clin Endocrinol Metab. 2016 Jan;101(1):1-5. doi: 10.1210/jc.2015-2169. Epub 2015 Nov 10.</citation>
    <PMID>26555935</PMID>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2013</study_first_submitted>
  <study_first_submitted_qc>October 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2013</study_first_posted>
  <last_update_submitted>November 2, 2017</last_update_submitted>
  <last_update_submitted_qc>November 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospitals and Clinics of Minnesota</investigator_affiliation>
    <investigator_full_name>Kris Ann Schultz</investigator_full_name>
    <investigator_title>Kris Ann P. Schultz, MD, MS</investigator_title>
  </responsible_party>
  <keyword>ovarian</keyword>
  <keyword>testicular</keyword>
  <keyword>stromal</keyword>
  <keyword>Sertoli</keyword>
  <keyword>Leydig</keyword>
  <keyword>gynandroblastoma</keyword>
  <keyword>juvenile granulosa cell tumor</keyword>
  <keyword>DICER1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Small Cell</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

